Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation

Detalles Bibliográficos
Autores principales: Mao, Shiqi, Luo, Libo, Yang, Shuo, Wang, Yan, Zhou, Fei, Yu, Jia, Chen, Bin, Gao, Guanghui, Li, Xuefei, Zhao, Chao, Cheng, Lei, Liu, Yiwei, Wang, Wanying, Jia, Keyi, Shao, Chuchu, Liu, Xinyu, Chen, Xiaoxia, Su, Chunxia, Zhou, Caicun, Wu, Fengying, Ren, Shengxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150891/
https://www.ncbi.nlm.nih.gov/pubmed/36921117
http://dx.doi.org/10.1097/CM9.0000000000002453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150891/
https://www.ncbi.nlm.nih.gov/pubmed/36921117
http://dx.doi.org/10.1097/CM9.0000000000002453

Ejemplares similares